top of page
רקע כהה למעלה
CorNeat EverPatch_no background2.png

CorNeat EverPatch 

Permanent tissue-integrating ophthalmic surgical matrix

About Ophthalmic Reconstructive Surgery

Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible, making patching the area with preserved and processed tissue the only treatment option.


CorNeat KPro

רקע כהה למעלה

CorNeat EverPatch Advantages 



 Inert and non-degradable material –
Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response


Ease of


 Extremely easy to handle and suture


Elastic and durable (cannot be torn by the sutures)



Synthetic and therefore cannot carry or transmit disease


Thin (100 microns), minimizing risk of dellen




Reduces operating time and eye bank costs


Eliminates complexities related to the transportation and storage of biological materials


Readily available, off-the-shelf, device 



Translucent when wet

Hardly visible when implanted 


Eye contact4_Shutterstock.jpg

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and nondegradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.   
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue. 


Reinforcing the sclera and aiding the physical reconstruction of the ocular surface

Concealing irritating ophthalmic implants such as glaucoma tube shunts and scleral sutures, used in scleral fixations of IOLs, displacing the need for preserved tissue/collagen

Covering tissue gaps/weaknesses, resulting either from traumatic, disease related or iatrogenic damage

Eye contact3_Shutterstock.jpg
רקע כהה למעלה

Regulatory Path

FDA Clearance

The CorNeat EverPatch is following a 510(k) clearance path, after submitting all necessary documents to the FDA in September 2022. The 510(k) submission is based on numerous tests and assessments which include a long-term animal trial, usability assessment and numerous R&D tests. The device is expected to be approved for marketing in the US and in FDA adopting countries early in 2023, with the following intended use: implantation to reinforce the sclera and aid the physical reconstruction of the ocular surface.

CE Marking

The current pivotal trial is geared toward obtaining a CE Marking early in 2024, for wider indications that include: the concealment of artificial ophthalmic implants, such as glaucoma shunts and scleral sutures used in scleral fixations of IOLs, from the overlying conjunctiva.

The plans above are subject to regulatory approvals and requirements.

For more information about the FIH clinical trial click here, for more information about the pivotal trial click here.

Anchor 1

Product Animation 

bottom of page